PUBLICATIONS
Peer-reviewed ORIGINAL PAPERS
1. Dryden MS. C-reactive protein concentration in suspected bacteraemia. J Clin
Pathol. 1986 Dec;39(12):1363-4. PubMed PMID: 3805324; PubMed Central PMCID:
PMC1140805.
1. Dryden MS. A pathogenic role for Bacillus cereus in wound infections in the
tropics. J Roy Soc Med 1987; 80: 8. 480-481.
2. Dryden MS, Kramer JM. Toxigenic Bacillus cereus as a cause of wound infections
in the tropics. J Inf 1987; 15: 207-212.
3. Gardener TD, Flanagan P, Dryden MS, Costello C, Shanson DC, Gazzard BC.
Disseminated Mycobacterium avium-intracellulare infection and red-cell hyperplasia
in patients with AIDS. J Inf 1988; 16: 135-140.
4. Shanson DC, Dryden MS. Comparison of methods for isolating Mycobacterium
avium-intracellulare from the blood of patients with AIDS.J Clin Path 1988; 41: 687690.
5. Connolly GM, Dryden MS, Shanson DC, Gazzard BC. Cryptosporidial diarrhoea in
AIDS and its treatment. Gut 1988; 29: 593-597.
6. Dryden MS, Shanson DC. The microbial causes of diarrhoea in HIV positive
patients.J Inf 1988; 17: 107-114.
7. Dryden MS, Munro R. Aeromonas species septicaemia: relationship of biotypes
and clinical features. Pathology 1989. 21: 111-114.
8. Dryden MS. Antibiotic resistance in Enterococci at a teaching hospital. Pathology
1989. 21: 177-179.
9. Fletcher J, Dryden MS, Munro R, Xu JH, Hehir MD. Establishment of a vascular
graft infection model in the sheep carotid artery. Aust.NZ.J.Surg. 1990. 60: 801-803.
10. Dryden MS, Wing AJ, Phillips I. Low dose intraperitoneal ciprofloxacin for the
treatment of peritonitis in patients receiving continuous ambulatory peritoneal
dialysis. J Antimicrob Chemother 1991. 28: 131-139.
11. Dryden MS, Ludlam HA, Wing AJ, Phillips I. Active intervention dramatically
reduces CAPD-associated infection. Advances in Peritoneal Dialysis 1991: 7; 125-128.
12. Dryden MS, Samson A, Ludlam HA, Wing AJ, Phillips I. Infective complications
associated with the use of the Quinton Permcath for long-term central vascular
access in haemodialysis. J Hosp Infect 1991: 19; 257-262.
13. Dryden MS, Talsania HG, Martin S, Cunningham M, Richardson JF, Cookson B,
Marples RR, Phillips I. Evaluation of supplementary methods for typing coagulasenegative staphylococci. J Med Microbiol 1992: 37; 109-117.
14. Dryden MS, Talsania H, McCann M, Cookson BD, Phillips I. The epidemiology of
ciprofloxacin resistance in coagulase-negative staphylococci. J Epidem Infect 1992:
109; 97-112.
15. Dryden MS, McCann M, Wing AJ, Phillips I. Controlled trial of a Y-set delivery
system to prevent peritonitis in patients receiving continuous ambulatory peritoneal
dialysis. J Hosp Infect 1992: 20; 185-192.
16. Dryden MS, Talsania H, Rodgers J, Bayston R, Phillips I. Serological response to
coagulase-negative staphylococci in patients on continuous ambulatory peritoneal
dialysis. Eur J Clin Microbiol Infect Dis. 1993: 87-92.
17. Dryden M, Cookson B, Talsania H, Phillips I. Typing of staphylococci by SDS-PAGE
and Immunoblotting, and epidemiology of ciprofloxacin resistance in staphylococcal
isolates from CAPD patients. In Staphylococci and staphylococcal infections. Mollby,
Flock, Nord, Christensson (eds). Gustav Fisher Vaerlag. Stuttgart. 1994.
18. Dryden MS, Talsania H, Phillips I. Immunoblot analysis of staphylococcal
antibodies in CAPD patients with staphylococcal peritonitis. In Staphylococci and
staphylococcal infections. Mollby, Flock, Nord, Christensson (eds). Gustav Fisher
Vaerlag. Stuttgart. 1994.
19. Young KA, Power EGM, Dryden MS, Phillips I. RAPD typing of clinical isolates of
Staphylococcus haemolyticus. Lett Appl Microbiol. 1994: 18; 86-89.
20. Dryden MS, Wilkinson M, Redman M, Millar MR. Detection of Chlamydia
trachomatis in general practice urine samples. Brit J Gen Practice. 1994: 44; 114-117.
21. Dryden MS, Keyworth N, Gabb R, Stein K. Asymptomatic foodhandlers as the
source of nosocomial salmonellosis. Journal of Hospital Infection. 1994: 28; 195-208.
22. Dryden MS, Gabb RJE, Wright SK. Empirical ciprofloxacin, in the treatment of
severe acute gastroenteritis in the community. Clinical Infectious Diseases. 1996; 22:
1019-25
23. Sundkvist T, Dryden MS, Gabb R, Soltanpoor N, Casemore D, Stuart J. Outbreak of
cryptosporidiosis associated with a swimming pool. CDR 1997; 12: 190-192.
24. Asumang A, Goldsmith AL, Dryden MS. Subcutaneous nodules with Pseudomonas
septicaemia in an immunocompetent patient. Anaesth Intensive Care 1999; 27:213215
25. Samuel AW, Dryden MS, Shepherd HA. Vertebral osteomyelitis caused by
Haemophilus paraphrophilus. 1999
26. Mark Wilcox, Dilip Nathwani, Mathew Dryden. Linezolid compared with
teicoplanin for the treatment of suspected or proven Gram-positive infections J
Antimicrob Chemother Journal of Antimicrobial Chemotherapy (2004) 53, 335-344
27. Matthew Dryden, Madhu Ramakrishnan, Julian Elford, Stephanie DamoaSiakwan; A case of extensive intracerebral infection. Infection CPD, 2003 4,2:49-52
28. Dryden MS, Dailly S, Crouch M. A randomised, controlled study of tea tree topical
preparations versus a standard topical regimen for the clearance of MRSA carriage.J
Hosp Infection 2004 56, 283-286
29. Balsezak S, Williams E, Dryden MS, A case of Job syndrome: delayed presentation
of multiple skin abscesses. CPD Infection 2004; 4: 80-81
30. Weigelt J., K. Itani, D. Stevens, W. Lau, M. Dryden, C. Knirsch, and the Linezolid
CSSTI Study Group. 2005. Linezolid versus vancomycin in treatment of complicated
skin and soft tissue infections. Antimicrob Agents Chemother. 49:2260-2266.
31. S. Jackson, M. Dryden, P. Gillett, P. Kearney and R. Weatherall A novel
midstream urine collection device improves contamination rates in urine cultures.
British Journal of Urology 2005 96:360-364
32. Matthew Dryden, Roberta Parnaby, Sue Dailly, Theresa Lewis, Karen Davis-Blues;
Jonathan A. Otter2, Angela M. Kearns. Hydrogen peroxide vapor (HPV)
decontamination in the control of a polyclonal MRSA outbreak on a surgical ward J
Hosp Inf 2008 68; 190-192
33. Nathwani D, Morgan M, Masterton R, Dryden M, Cookson B, French G, Lewis D.
Guidelines for UK practice for the diagnosis and management of MRSA infections
presenting in the community. Journal of Antimicrob Chemotherapy. 2008
doi:10.1093/jac/dkn096
34. Dryden MS. Complicated Skin and Soft Tissue Infections Caused by MethicillinResistant Staphylococcus aureus: Epidemiology, Risk Factors, and Presentation.
SURGICAL INFECTIONS Volume 9, Supplement 1, 2008
35. Dryden MS. Skin and soft tissue infection: microbiology and epidemiology.
International Journal of Antimicrobial Agents 33, S3 (2009) S2–S7.
36. Dryden MS, Cooke J, Davey P. Antibiotic stewardship – more education and
regulation not more availability? Journal of Antimicrob Chemotherapy. 2009; 64,
885–888
37. Dryden MS, Hand K, Davey P. Antibiotics for Community-acquired pneumonia.
Journal of Antimicrob Chemotherapy. 2009; 64:1123-1125
38. Itani K, Dryden MS, Bhattacharyya H, Kunkel MJ, Baruch AM. Weigelt JA, Efficacy
and safety of linezolid versus vancomycin for the treatment of complicated skin and
soft-tissue infections proven to be due to methicillin-resistant Staphylococcus aureus
The American Journal of Surgery 2009 10.1016/j.amjsurg.2009.08.045. Epub ahead
of print, March 12, 2010.
39. Gian M. Rossolini , Matthew S. Dryden , Roman S. Kozlov, Alvaro Quintana,
Robert K. Flamm, Jörg M. Läuffer, Emma Lee, Ian Morrissey. Comparative activity of
ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the
Middle East, the CLASS study. JAC 2010 in press
40. M. Dryden, A. T. Andrasevic, M. Bassetti, E. Bouza, J. Chastre, G. Cornaglia, S.
Esposito, G. French, H. Giamarellou,I. C. Gyssens, D. Nathwani, S. Unal , A. Voss. A
European survey of antibiotic management of methicillin-resistant Staphylococcus
aureus infection: current clinical opinion and practice. Clin Microbio Infect 2010; 16
(suppl 1) 3-30
41. K. Saeed, MS Dryden ,S. Bourne, C Paget, A. Proud. Reduction in antibiotic use
through procalcitonin testing in patients in the medical admission unit or intensive
care unit with suspicion of infection, Journal of Hospital Infection (2011),
doi:10.1016/j.jhin.2011.03.018
42. N. McFARLAND, M. DRYDEN, M. RAMSAY, R. S. TEDDER and S. L. NGUIa4 An
outbreak of hepatitis A that affected a nursery school, a primary school and a
hospital. Epidemiology and Infection. 2010 DOI: 10.1017/S0950268810001433
43. Saeed K, Dryden M, Parnaby R. JHI 2010 in press. Oxacillin-senstive, mec A
positive MRSA
44. Schaper N, Dryden M, Kujath P, et al. Efficacy of IV/PO moxifloxacin and IV
piperacillin/tazobactam followed by PO amoxicillin-clavulanate in the treatment of
diabetic foot infections: results of the RELIEF study Clinical Microbiology and
Infection. Volume 16 Supplement No. 2, Page S449
45. Dryden M. Complicated skin and soft tissue infection J Antimicrob Chemother
2010; 65 Suppl 3: iii35–44 doi:10.1093/jac/dkq302
46. Gian M. Rossolini; Matthew S. Dryden; Roman S. Kozlov; Alvaro Quintana; Robert
K. Flamm; Jorg M. Lauffer; Emma Lee; Ian Morrissey Comparative activity of
ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the
Middle East: the CLASS study ; on behalf of the CLASS study group. Journal of
Antimicrobial Chemotherapy 2010; doi: 10.1093/jac/dkq397
47. Eckmann C, Dryden M. Treatment of complicated skin and soft-tissue infections
caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and
vancomycin. Eur J Med Res 2010; 15: 1-10.
48. Eckmann C, Dryden M, Montravers F, Kozlov R, Sganga G. Antimicrobial
treatment of "complicated" intra-abdominal infections and the new IDSA guidelines a commentary and an alternative European approach according to clinical
definitions. .Eur J Med Res (2011) 16: 115-126
49. Matthew S. Dryden Linezolid pharmacokinetics and pharmacodynamics in clinical
treatment Journal of Antimicrobial Chemotherapy 2011 66: iv7-iv15
50. Gyssens, Inge; Dryden, Matthew; Kujath, Peter; Nathwani, D.; Schaper, Nicolaas;
Hampel, Barbara; Reimnitz, Peter; Alder, Jeff; Arvis, Pierre A randomized trial of the
efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy vs
intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for
complicated skin and skin structure infections. J Antimicrob Chemother. 2011
accepted July 2011
51. Dryden MS, Johnson AP, Ashiru-Oredope D, Sharland M. Using antibiotics
responsibly: right drug, right time, right dose, right duration. J Antimicrob
Chemother 2011 doi:10.1093/jac/dkr370
52. Esposito. S, Bassetti, M, Borre S, Bouza E, Dryden M et al. Diagnosis and
management of skin and soft tissue infection – a review. Journal of Chemotherapy.
2011, 23: 251-262
53. GUIDELINES FOR PREVENTION AND CONTROL OF GROUP A STREPTOCOCCAL
INFECTION IN ACUTE HEALTHCARE AND MATERNITY SETTINGS IN THE UK
Corresponding Author: Dr Joe Kearney Submitted to: Journal of Infection In press
54. Skov R, Christiansen K, Dancer SJ, Daum RS, Dryden M, Huang YC, Lowy FD.
Update on the prevention and control of community-acquired meticillinresistant Staphylococcus aureus (CA-MRSA). Int J Antimicrob Agents 2012 Jan 6.
[Epub ahead of print]
55. M. Dryden; K. Saeed; R. Townsend; C. Winnard; S. Bourne; N. Parker; J. Coia; B.
Jones; W. Lawson; P. Wade; P. Howard; S. Marshall
Antibiotic stewardship and early discharge from hospital: impact of a structured
approach to antimicrobial management
Journal of Antimicrobial Chemotherapy 2012; doi: 10.1093/jac/dks193
56. Alastair Gray, Matthew Dryden and Apostolos Charos. Antibiotic management
and early discharge from hospital: an economic analysis. 2012 J Antimicrob
Chemother doi:10.1093/jac/dks194
LETTERS
Dryden MS. C-Reactive Protein in suspected bacteraemia. J Clin Path 1986; 39: 136364.
Dryden MS. Resistant Enterococci. Australian Society for Microbiology Newsletter
November 1988.
Dryden MS, Legarde M, Gottlieb T. Vibrio damsela wound infections in Australia.
Med J Aust. 1989. 151: 540-541.
Ludlam H, Dryden MS, Wing AJ, Phillips I. Prevention of peritonitis in continuous
ambulatory peritoneal dialysis. Lancet 1990 335: 1161.
Dryden MS, Ludlam HA, Phillips I. 4-Quinolone resistant staphylococci. J Antimicrob
Chemother. 1990 26: 448-449.
Ludlam HA, Dryden MS, Barton I, Phillips I. Short course ciprofloxacin therapy for
CAPD peritonitis. J Antimicrob Chemother 1990 26: 162-164.
Dryden MS, McCann M, Phillips I. Housewife peritonitis: conjugal transfer of a
pathogen. J Hosp Inf 1991 17: 69-70
Ludlam HA, Dryden MS, Phillips I. Ciprofloxacin and CAPD peritonitis. J Antimicrob
Chemother 1991 27: 684-685.
Dryden MS, Ludlam HA, Phillips I. Ciprofloxacin-resistant methicillin-sensitive
Staphylococcus aureus. J Hosp Inf 1991 17: 319-321.
Dryden MS, Jones NF, Phillips I. Failure of Listeria peritonitis in a CAPD patient to
respond to vancomycin therapy. J Infect Dis 1991: 164; 1239.
Dryden MS, Gabb R. Notifiable diseases. BMJ: 1992: 304; 1056.
Dryden MS, Eykyn SJ. Short course gentamicin in Gram-negative CAPD peritonitis.
Lancet 1993: 341; 497.
Dryden MS, Dalgliesh D. Pasteurella multocida from a dog causing Ludwig's angina.
Lancet 1996; 347: 123.
Dryden MS, O'Connell S, Samuel W, Iannotti F. Lyme myelitis mimicking neurological
malignancy. Lancet 1996; 348: 642.
Matthew Dryden, Laura J. V. Piddock BMJ Rapid responses on line (23 July 2009)
Pandemic influenza and antibiotics
http://www.bmj.com/cgi/eletters/339/jul06_1/b2698
Saeed, Kordo; Stannard, Timothy; Dryden, Matthew; Lambert, Helen. One for all'
concerns regarding NICE antibiotic guidelines on suspected bacterial meningitis!
British Journal of General Practice, Volume 61, Number 591, October 2011 , pp. 606606(1)
REVIEWS
Dryden MS. Problems associated with the use of antibiotics. Pharmacy Update 1987;
3: 7. 258-264.
Dryden MS. Current trends in antibiotics. Part 1: The beta-lactam and macrolide
antibiotics. Pharmacy Update 1987; 3: 347-350.
Dryden MS. Aminoglycosides, Quinolones and other antibiotics. Pharmacy Update
1987; 3: 391-394.
Dryden MS. Topical anti-infective preparations. Pharmacy Update 1988; 4: 1. 15-16.
Dryden MS. The control of Salmonella outbreaks in hospitals: a practical guide. Bugs
and Drugs 1996; 2: 1-3
Dryden MS. Book review: Medical Microbiology Mimms et al ISBN 0-7234-2781-X
in J Hosp Infection 1998
Dryden MS. Book review. Oxford Handbook of Infectious Diseases and Microbiology
E. Torok, E. Moran and F. Cooke. Oxford University Press, 2009. JAC Advance Access
published on August 26, 2009; doi: doi:10.1093/jac/dkp308
CHAPTERS
Dryden MS. The interaction between the microbiologist and other specialists with
the hospital and the community. In Setting the Standards Ed. O'Brien TF. 1994.
Wells Medical Ltd. Tunbridge Wells. ISBN 1859390250
Dryden MS, Tapp A. Obstetric and Gynecologic infections. In The role of
piperacillin/tazobactam in the treatment of polymicrobial infections. Ed. Nord CE.
1994 Pharmanual. Montreal. ISBN 0-919838-45-2
Dryden MS. Topical versus systemic antimicrobial therapy in the treatment of skin
infections. In The Clinical Efficacy of Mupirocin in the Treatment of Skin Infections.
Ed. K. Bork. Wells Medical Ltd. Tunbridge Wells. 1996. ISBN 1859390404
Dryden MS. Medical problems of environmental extremes: tropics and deserts. In
Expedition Medicine. The Royal Geographical Society. Profile Books. 1998. IBSN 1
86197 040 4.
Dryden MS. Acute infections. In Expedition Medicine. The Royal Geographical
Society. Profile Books. 2002.
Dryden MS. Leptospirosis. In Traveller’s Health 5th Edition, OUP 2011
Dryden MS. Skin and Soft tissue infection. In Traveller’s Health 5th Edition, OUP
2011
Matthew Dryden, Jean-Phillippe Lavigne. The Diabetic foot. The European Manual of
Clinical Microbiology. ESCMID ISBN: 978-2-87805-026-4. 2012
BOOK
Dryden MS. Patholog, a pathology services manual. Euromed Communications. 1998.
ISBN 1-899-015-310
ABSTRACTS & PRESENTATIONS AT NATIONAL/INTERNATIONAL MEETINGS
1. Chew.W. Dryden M.S. Atypical Mycobacteria and soft tissue infection.
Proceedings of the annual general meeting of the Australian Society for
Microbiology. 1989.
2. Dryden.M.S. Ludlam.H.A. Barton.I. Phillips I. Intraperitoneal ciprofloxacin for
the treatment of peritonitis in patients on CAPD. 2nd International
Conference of the Hospital Infection Society. 1990.
3. Dryden MS, Ludlam HA, Wing AJ, Phillips I. Active intervention dramatically
reduces CAPD-associated infection. Perit. Dial. Int. 1991 11: suppl. 1, 73.
4. Dryden MS, Phillips I. Correlation of in vitro sensitivity and clinical efficacy in
the use of ciprofloxacin to treat CAPD peritonitis. Proceedings of the 17th
International Congress of Chemotherapy. 1991. Abstract 1897.
5. Dryden MS. Comparison of blood culture methods in paediatric septicaemia:
Isolator 1.5 and BacT/Alert. 7th International Conference of Infectious
Diseases. Hong Kong 1996
6. Dryden MS. Linezolid, a new oxazolidinone, Phase II clinical trials results. Fifth
conference of the Federation of Infectious Societies, Manchester November
1998
7. Dryden MS. Role of new antimicrobials: Bloodstream Infections. Ninth
European Conference of Clinical Microbiology and Infectious Diseases, Berlin
March 1999
8. Dryden MS. Clinical experience with Linezolid. Br Soc for Haematology, 39th
Annual Scientific Meeting, Brighton April 1999
9. Dryden MS. Linezolid for serious Gram positive infections. Intensive Care
Society Spring Meeting, Edinburgh May 1999
10. Dryden MS.Clinical applications of oxazolidinones. International meeting on
Antimicrobial Chemotherapy. Int Soc of Chemotherapy. October 1999.
11. Dryden MS. Clinical efficacy and safety of novel oxazolidinones. European
Congress of Chemotherapy. Madrid. May 2000.
12. Dryden MS, Wilcox M, Nathwani D. Are oxazolidoniones clinically superior to
glycopeptides? Int Congress of Chemotherapy June 2003
13. Dryden M, N. Chaudry, A. Reisman, J. Weigelt. Linezolid versus vancomycin
for culture-proven complicated skin and soft tissue infections - trends of
subjects enrolled in Europe and globally in a global study. 14th ECCMID
Prague May 2004.
14. Matthew Dryden, Royal Hampshire County Hospital, Winchester, UK; Heather
Gentry , Theresa Merreday, Worcester Acute Hospitals, NHS Trust,
Worcester; Pauline Westbrook, Dept of Microbiology, Trafford General
Hospital, Manchester; Karen Almond, Leylands Medical Centre, North
Bradford PCT, UK. Improving the quality of mid-stream urine samples with a
collection device. ICAAC 2007. PROGRAMME COMMITTEE AWARD FOR
OUTSTANDING ABSTRACT PRESENTAION IN THE FIELD OF MICROBIOLOGY
AND DIAGNOSIS.
15. Matthew Dryden, Roberta Parnaby, Sue Dailly, Theresa Lewis, Karen DavisBlues Royal Hampshire County Hospital, Winchetser, UK; Jonathan A. Otter,
BIOQUELL (UK) Ltd., Andover, UK; Angela M. Kearns, Staphylococcus
Reference Laboratory, Health Protection Agency, London, UK. Environmental
decontamination with hydrogen peroxide vapor (HPV) in the control of an
MRSA outbreak. . ICAAC 2007
16. Dryden M, O’Hare MD, Sidarous E, Hadváry P, and Islam K. Clinical Efficacy of
Iclaprim in Complicated Skin and Skin Structure Infections (cSSSI): Preliminary
Results of ASSIST-2 Clinical Trial. ECCMID 2008, Poster
17. Hadvàry P., Dryden M, O’Hare M, Burley C, Sidarou E, Leighton A and Islam,
K..Assessment of Safety and Tolerability Profiles after Iclaprim Administration
in Complicated Skin and Skin Structure Infection (cSSSI) from the ASSIST-2
Clinical Trial. ECCMID 2008, Poster
18. Hadváry P, Dryden M, O’Hare M, Dankner W and Islam, K. Analysis of the
Effect of Iclaprim on the QT Interval in the ASSIST-2 Clinical Trial. ECCMID
2008, Poster
19. E. Bouza, M. Dryden, R. Mohammed, J. Peppe, S. Chasan-Taber, J. Donovan,
D. Davidson, G. Short. Results of a phase III trial comparing tolevamer,
vancomycin and metronidazole in patients with Clostridium difficileassociated diarrhoea. ECCMID 2008, Oral presentation.
20. K. Itani, J. Weigelt, D. Stevens, M. Dryden, H. Bhattacharyya, M. Kunkel, A.
Baruch. Efficacy and safety of linezolid versus vancomycin for the treatment
of complicated skin and soft-tissue infections proven to be due to meticillinresistant Staphylococcus aureus ICAAC 2008
21. P. Hadváry1*, W. Dankner2, A. Leighton1, M. Dryden3, D. Stevens4, and K.
Islam1. Iclaprim effect on the QT Interval: Results of Combined ASSIST Phase 3
Studies. ICAAC 2008
22. P. Hadváry1, D. Stevens2, M. Solonets1, M.E. Jones1, D. F. Sahm3, M. D.
O’Hare4, W. Danker5, A. Leighton1, M.Dryden 6, and K.1 Islam1 Clinical Efficacy
of Iclaprim in Complicated Skin and Skin Structure Infection (cSSSI): Results of
Combined ASSIST Phase III Studies. ICAAC 2008
23. K.M.F. Itani* J. Weigelt, D.L. Stevens, M.S. Dryden, H. Bhattacharyya, M.
Kunkel, A. Baruch, *V.A Efficacité et tolérance du linézolide (LZD) versus
vancomycine (VAN) dans le traitement des infections compliquées de la peau
et des tissus mous (ICPTM) documentées à SARM Boston Healthcare System,
Boston, USA, kitani@va.gov. Société de Pathologie Infectieuse de Langue
Français et du College des Universitaires de Maladies Infectieuses et
Tropicales. Lyon June 2009.
24. Inge Gyssens, Matthew Dryden, Peter Kujath, Dilip Nathwani, Nicolaas
Schaper, Pierre Arvis, Peter Reimnitz, Jeff Alder, Barbara Hampel. Efficacy of
IV/oral moxifloxacin in the treatment of complicated skin and skin structure
infections: results of the RELIEF study. ECCMID 2009
25. Inge Gyssens, Matthew Dryden, Peter Kujath, Dilip Nathwani, Nicolas
Schaper Pierre Arvis, Peter Reimnitz, Jeff Alder, Barbara Hampel. Efficacy of
IV/oral moxifloxacin and IV piperacillin/tazobactam followed by oral
amoxicillin/clavulanic acid in the treatment of major abscess: results of the
RELIEF study. ECCMID 2009
26. Schaper N, Dryden M, Kujath P, et al. Efficacy of IV/PO moxifloxacin and IV
piperacillin/tazobactam followed by PO amoxicillin-clavulanate in the
treatment of diabetic foot infections: results of the RELIEF study. 2010
Presented at the 20th European Congress of Clinical Microbiology and
Infectious Diseases; poster 1550
27. M. DRYDEN1, K. SAEED 1, P. Howard2, S. BOURNE 1, N. PARKER 1, J Coia, K
Bamford, P.Wade, S. MARSHALL Antibiotic management and early discharge
from hospital. Federation of Infection Societies, Edinburgh, November 2010
28. A.M. Gray*, M. Dryden, A. Charos (Oxford, Winchester, Walton-on-the-Hill,
UK) Antibiotic management and early discharge from hospital: an economic
analysis. ECCMID 2011
OTHER MEDICAL TOPICS
Dryden MS. An expedition across the Okavango.Brit Med J 1982; 285: 1832-34.
Dryden MS. Along the White Nile. Br Med J 1983; 286: 1883-85.
Dryden MS. Uncertainty over the measles vaccine. The Times 20th October 1994 p
21.
Dryden MS. Consultant Script writer and editor. BBC Radio 4 drama ‘ Pandemic’.
Goldhawk productions 2011